<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Helwick, Caroline</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Califf, Robert M.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Update on Antithrombotic Therapy</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2007</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2007-05-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">31-33</style></pages><abstract><style  face="normal" font="default" size="100%">With the introduction of several new antiplatelet and anticoagulant agents that have multiple actions and interactions, selection of the optimal antithrombotic has become quite complex. This article discusses direct Xa inhibitors, direct thrombin inhibitors, GP IIb/IIIa inhibitors, adenosine diphosphate inhibitors, as well as novel targets for antithrombotic therapy.</style></abstract><number><style face="normal" font="default" size="100%">1</style></number><volume><style face="normal" font="default" size="100%">7</style></volume></record></records></xml>